Antiretroviral drug concentrations in semen of HIV-1 infected men

被引：77

作者：

Taylor, S ^{[1
]}

Pereira, AS

机构：

[1] Univ Birmingham, Div Immun & Infect, PHLS Antiviral Susceptibil, Birmingham B15 2TT, W Midlands, England

[2] Birmingham Heartlands Hosp, Dept Sexual Med, Birmingham, W Midlands, England

[3] Univ N Carolina, Dept Pathol & Lab Med, Chapel Hill, NC 27599 USA

来源：

SEXUALLY TRANSMITTED INFECTIONS | 2001年 / 77卷 / 01期

关键词：

HIV; semen; antiretrovirals; drug concentrations; pharmacokinetics; protein binding;

D O I：

10.1136/sti.77.1.4

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

Because semen is a major vehicle for the sexual transmission of HIV-1, control of viral replication within the sanctuary of the male genital tract should be a goal of antiretroviral therapy. Local immune responses, virus specific factors, and the degree of viral and cellular trafficking all appear to be important in controlling viral replication and evolution. However, the most important factor influencing viral replication and evolution within the male genital tract may be the disposition of antiretroviral agents into genital tissues and fluids. This review proposes possible mechanisms of antiretroviral distribution into the male genital tract by using other sanctuary barriers; such as the placenta, renal tubules, and blood-brain barrier; as models. In addition, this review summarises recent clinical studies regarding the disposition of currently available antiretroviral drugs into the seminal plasma and discusses some of the difficulties in interpreting drug concentration in the genital tract.

引用

页码：4 / 11

页数：8

共 66 条

[1]

AIBA T, 1995, J PHARMACOL EXP THER, V272, P94

[2] EFFECTS OF DISEASE STAGE AND ZIDOVUDINE THERAPY ON THE DETECTION OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 IN SEMEN [J].

ANDERSON, DJ ;

OBRIEN, TR ;

POLITCH, JA ;

MARTINEZ, A ;

SEAGE, GR ;

PADIAN, N ;

HORSBURGH, CR ;

MAYER, KH .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1992, 267 (20) :2769-2774

[3] Semen and serum pharmacokinetics of zidovudine and zidovudine-glucuronide in men with HIV-1 infection [J].

Anderson, PL ;

Noormohamed, SE ;

Henry, K ;

Brundage, RC ;

Balfour, HH ;

Fletcher, CV .

PHARMACOTHERAPY, 2000, 20 (08) :917-922

[4]

BENDAYAN R, 1995, PHARMACOTHERAPY, V15, P338

[5]

BLASCHKE AH, 2000, 7 C RETR OPP INF

[6] The maternal-fetal transfer of lamivudine in the ex vivo human placenta [J].

Bloom, SL ;

Dias, KM ;

Bawdon, RE ;

Gilstrap, LC .

AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1997, 176 (02) :291-293

[7] Pharmacokinetic and toxicity studies of AZT (zidovudine) following perfusion of human term placenta for 14 hours [J].

Boal, JH ;

Plessinger, MA ;

VandenReydt, C ;

Miller, RK .

TOXICOLOGY AND APPLIED PHARMACOLOGY, 1997, 143 (01) :13-21

[8] HIV-1 drug resistance in newly infected individuals [J].

Boden, D ;

Hurley, A ;

Zhang, LQ ;

Cao, YZ ;

Guo, Y ;

Jones, E ;

Tsay, J ;

Ip, J ;

Farthing, C ;

Limoli, K ;

Parkin, N ;

Markowitz, M .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1999, 282 (12) :1135-1141

[9] HIV-1 in semen: an isolated virus reservoir [J].

Byrn, RA ;

Zhang, DZ ;

Eyre, R ;

McGowan, K ;

Kiessling, AA .

LANCET, 1997, 350 (9085) :1141-1141

[10]

CHATTON JY, 1990, J PHARMACOL EXP THER, V255, P140

← 1 2 3 4 5 6 7 →